Navigation Links
Positive Results from Phase 2 Trial of Mesoblast's Adult Stem Cell Therapy Presented at the American Heart Association Annual Meeting
Date:11/14/2011

tion of heart failure hospitalization events.  Mesoblast expects that these outcomes will be central to the primary endpoint of a Revascor™ Phase 3 trial for product regulatory approval by the United States Food and Drug Administration (FDA).

The randomized, placebo-controlled 60-patient Phase 2 trial compared the safety and efficacy of three doses of Revascor™ on top of maximal approved therapies versus maximal therapies alone in patients with moderate-to-severe congestive heart failure (CHF) defined by New York Heart Association (NYHA) class II or III status and ejection fraction below 40%.  The trial enrolled both ischemic and non-ischemic heart failure patients.  Heart failure patients with this degree of severity are known to have a high cardiac mortality over a 12-24 month period despite being on maximal approved drug and device therapies.

Treatment with MPCs was well-tolerated, with 13% of patients developing transient or persistent anti-donor antibodies which were without clinical consequence. Over a 22-month mean follow-up period, only 1/45 (2%) patients who received a single injection of Revascor™ died of cardiac causes compared with 3/15 (20%) controls (p=0.02).  In addition, MPC treatment significantly delayed the time to a first Major Adverse Cardiac Event, MACE, a composite of cardiac death, heart attack or revascularization procedures (p=0.036), and reduced the overall risk for MACE by 78% (p=0.011).

Over a mean follow-up of 18 months, 0/15 patients who received the highest dose of MPC (150M) had been hospitalized for heart failure or had died.  In contrast, 3/15 (20%) controls and 6/30 (20%) patients who received low (25M) or mid (75M) doses of MPC had either been hospitalized with heart failure or had died. This clinical improvement associated with the 150M dose was accompanied by evidence of cardiac remodelling (reduction in left ventricular end systolic volumes compared with controls
'/>"/>

SOURCE Mesoblast
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Positive Data for Nektars New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011
2. Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation
3. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
4. Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
5. NeuroDerm Announces Positive Results of a Phase II Study of ND0611 Dermal Patch in Patients with Parkinsons Disease
6. Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
7. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
8. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
9. Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
10. Pharmaxis Announces Major Milestone: Positive Bronchitol Opinion for Europe
11. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... BOSTON , January 23, 2015 ... development company, is delighted to announce that the Malcolm ... Miles Congreve (Vice President of Chemistry), Fiona ... Weir (Chief Executive Officer and co-founder) for the seminal ...
(Date:1/22/2015)... Jan. 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ), ... innovative proprietary products to treat voiding dysfunctions, today reported ... 31, 2014.  Global revenue for the Company,s ... million, a new quarterly revenue record, as compared to ...
(Date:1/22/2015)... Jan. 22, 2015  Bio-Techne Corporation (NASDAQ: TECH ... first member of the new Simple Plex platform through ... launch represents the re-branding of the previously acquired CyPlex ... platform is a transformative immunoassay technology which integrates an ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3
... Technologies Inc., the leading developer of non-invasive electrocardiographic ... $7.5 million Series "C" financing.  The proceeds from ... commercial efforts related to its ECVUE ™ ... (Logo: http://photos.prnewswire.com/prnh/20110531/DC10432LOGO ) CardioInsight recently ...
...  MAKScientific, LLC, a privately held company focused on the ... that it has entered into an exclusive, worldwide option ... BIIB ) to develop and commercialize drug candidates for ... diseases. Under the agreement, Biogen Idec will ...
Cached Medicine Technology:CardioInsight Announces Closing of $7.5 Million Equity Financing 2
(Date:1/22/2015)... January 23, 2015 VogueQueen is a seasoned ... prices and many designers are thrilled to have it lead ... announces its new collection of prom dresses for the global ... drive the strategic vision and he focuses on continuing the ...
(Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and David ... Show to bestow a Juvent Sports Achievement award upon ... McKitrick. The award commemorated and congratulated McKitrick for her ... won her first amateur tournament in 1979 and most ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television ... 32nd Annual Miami Breast Cancer Conference planned ... (PER®) , shares that “a fast-growing, virulent” cancer in ... had not followed up her clean mammogram with an ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... , July 16 Since January 2009, MediciGlobal has ... its work in patient education and design. In June, 2009 ... 2009 Communicator Awards from the International Academy of the ... was further notified of six more awards (two silver, and ...
... , , , ... nation,s first and largest provider of outsourced implantable medical device management solutions ... to chief executive officer. The appointment follows the company,s tenth quarter ... Healthcare Partners , a leading private equity firm focused exclusively on ...
... , WASHINGTON, July 16 "We,ll quit ... doctors at Health Care Freedom Tea Parties on July 17. , ... is joining the Tea Party Patriots to co-sponsor the protests at the ... clear that doctors and patients oppose government run medicine. , ...
... In an order filed on July 13, 2009, Judge Cecilia ... appointed as Lead Counsel to the Plaintiffs, Steering Committee in the ... in Parker Waichman Alonso LLP, and Scott Wm. Weinstein Esq., a ... Co-Lead Counsel,s responsibility is to represent the interests of ...
... 16 For the twelfth year in a row, National Jewish Health ... U.S. News & World Report . , , ... to recognize National Jewish Health as the best place in the nation ... Jewish Health. "Even in these challenging times, we are seeing more patients ...
... , COLUMBUS, Ohio, July 16 Mettler-Toledo International Inc. ... call to discuss the Company,s second-quarter results on Thursday, July 23, 2009 ... call, visit www.mt.com/investors on the Company,s website. A ... , , METTLER TOLEDO is a leading ...
Cached Medicine News:Health News:MediciGlobal Achieves Record Number of Awards 2Health News:Access MediQuip Names Tim Hargarten Chief Executive Officer 2Health News:Access MediQuip Names Tim Hargarten Chief Executive Officer 3Health News:ANDRES F. ALONSO, ESQ., a Partner in the Law Firm of PARKER WAICHMAN ALONSO LLP, Was Appointed Co-Lead Counsel to the Plaintiffs' Steering Committee in the Denture Cream Products Liability Litigation, MDL 2051 2Health News:National Jewish Health Named Top Respiratory Hospital for 12th Consecutive Year 2
... for cleaning, rinsing, disinfecting, and storing ... removes accumulations of film, deposits and ... harmful micro-organisms on the surface of ... lenses before insertion. Renu multi-purpose solution ...
Light weight adjustable trial frame, adult...
Children's Half Trial Frames...
Half Eye Trial Frame - Child...
Medicine Products: